Starpharma Holdings (ASX:SPL) Total Current Assets: A$24.24 Mil (As of Dec. 2025)


ASX:SPL Starpharma Holdings Ltd ASX:SPL
53 GF Score
Price A$0.70
GF Value A$0.43
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Starpharma Holdings Total Current Assets?

Starpharma Holdings ASX:SPL +0.72% 53 Total Current Assets is A$24.24 Mil as of Dec. 2025. GuruFocus rates ASX:SPL with a GF Score™ of 53/100 and a GF Value™ of A$0.43 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Starpharma Holdings's total current assets for the quarter that ended in Dec. 2025 was A$24.24 Mil.

Starpharma Holdings  (ASX:SPL) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Starpharma Holdings's Liquidation Value for the quarter that ended in Dec. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=18.248-4.688+0.75 * 4.173+0.5 * 1.823
=17.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starpharma Holdings Total Current Assets Related Terms

Starpharma Holdings Total Current Assets Historical Data

* Premium members only.

The historical data trend for Starpharma Holdings's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starpharma Holdings Total Current Assets Chart

Starpharma Holdings Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.76 60.66 47.12 32.92 22.56

Starpharma Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.53 32.92 26.25 22.56 24.24
ASX:SPL
53GF Score
Starpharma Holdings Ltd ASX:SPL
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starpharma Holdings Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Starpharma Holdings's Total Current Assets for the fiscal year that ended in Jun. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=15.407+4.225+1.915+1.013
=22.56

Starpharma Holdings's Total Current Assets for the quarter that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=18.248+4.173+1.823+0
=24.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of A$24.24 Mil mean?
Starpharma Holdings (ASX:SPL) has a Total Current Assets of A$24.24 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Starpharma Holdings and its competitors.
Is Starpharma Holdings' Total Current Assets too high?
Starpharma Holdings' current Total Current Assets is A$24.24 Mil. Overall, Starpharma Holdings has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' Total Current Assets compare to VRTX and REGN?
Starpharma Holdings' Total Current Assets of A$24.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Starpharma Holdings and its competitors. Starpharma Holdings's current Total Current Assets is A$24.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.43, compared to a current price of A$0.70 — trading 61.6% above its estimated fair value. The current Total Current Assets is A$24.24 Mil. Starpharma Holdings' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current Total Current Assets is A$24.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?

Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued. The current stock price of A$0.70 is trading 61.6% above its estimated GF Value™ of A$0.43. GuruFocus considers Starpharma Holdings to be Significantly Overvalued.

Key valuation signals for ASX:SPL:

  • Total Current Assets: A$24.24 Mil
  • GF Value™: A$0.43 vs. price of A$0.70 (61.6% above fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starpharma Holdings Business Description

Address 4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
53GF Score

Get the complete analysis for ASX:SPL

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.70
Price
A$0.43
GF Value